Biopharmaceutical company Soligenix, Inc. recently announced that its application for orphan drug designation for SGX945, developed for the treatment of Behçet's Disease, has received a positive opinion from the European Medicines Agency (EMA).

Biopharmaceutical company Soligenix, Inc. recently announced that its application for orphan drug designation for SGX945, developed for the treatment of Behçet's Disease, has received a positive opinion from the European Medicines Agency (EMA).

老虎证券2026/02/26 13:00

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

This significant development marks a key step forward in the development process of SGX945 for this rare inflammatory disease. Orphan drug designation is intended to encourage drug development for rare diseases and typically brings multiple policy benefits to companies, including a period of market exclusivity.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Biopharmaceutical company Soligenix, Inc. recently announced that its application for orphan drug designation for SGX945, developed for the treatment of Behçet's Disease, has received a positive opinion from the European Medicines Agency (EMA).

You may also like

Crypto prices